Advanced in Urea Cycle Disorders (UCD)

Adrien P. Bigot

49 Boulevard Béranger, 37 044 Tours Cedex 1, 
Tours, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Urea Cycle Disorders (UCD)
49 Boulevard Béranger, 37 044 Tours Cedex 1, 
Tours, FR 
OverviewLocationsClinical Research

Overview

Adrien Bigot practices in Tours, France. Bigot is rated as an Advanced expert by MediFind in the treatment of Urea Cycle Disorders (UCD). Their top areas of expertise are VEXAS Syndrome, Argininosuccinic Aciduria, Henoch-Schonlein Purpura, and Hypocomplementemic Urticarial Vasculitis.

Their clinical research consists of co-authoring 64 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 4 articles in the study of Urea Cycle Disorders (UCD).

Locations

49 Boulevard Béranger, 37 044 Tours Cedex 1, Tours, France
Other Locations
Strasbourg, 67000, France
Bordeaux, France
Angers, France
Lyon, France
France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
Enrollment Status: Recruiting
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drug: PTC923
Study Phase: Phase 3
Innate Immunity During Community Acquired Pneumonia: A Translational Approach
Innate Immunity During Community Acquired Pneumonia: A Translational Approach
Enrollment Status: Terminated
Publish Date: November 24, 2025
Intervention Type: Other
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drug: PTC923
Study Phase: Phase 3
View 2 Less Clinical Trial

64 Total Publications

Full recovery of vision following early and intensive hemodialysis in an 18-year-old woman with methylmalonic acidemia-related optic neuropathy.
Full recovery of vision following early and intensive hemodialysis in an 18-year-old woman with methylmalonic acidemia-related optic neuropathy.
Journal: Molecular genetics and metabolism reports
Published: August 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Bigot's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile